Suggestions

    SHOWING Results

    Pfizer and Novartis lead pharma spending spree on gene therapy

    Pfizer and Novartis lead pharma spending spree on gene therapy

    01 Dec 2019

    Eleven pharma companies led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing sector since 2018, according to a Reuters analysis, in...

    Novartis to buy biotechnology firm for $9.7 billion

    Novartis to buy biotechnology firm for $9.7 billion

    25 Nov 2019

    Novartis AG is buying US biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said, as it seeks to expand its portfolio of medicines against cardiovascular disease....

    Novartis to answer US Senate demand for data manipulation details

    Novartis to answer US Senate demand for data manipulation details

    19 Aug 2019

    Novartis plans to answer a US senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing...

    Novartis won US approval for its $2 million gene therapy

    Novartis won US approval for its $2 million gene therapy

    25 May 2019

    Swiss drugmaker Novartis on won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment...

    Novartis buys Takeda’s medicine brand

    Novartis buys Takeda’s medicine brand

    10 May 2019

    Novartis is buying dry-eye medicine brand ‘Xiidra’ from Takeda Pharmaceutical for up to $5.3 billion as the Swiss pharma-maker refreshes its ophthalmic medicines portfolio with a potential blockbuster. The deal...

    5 Results for

    Most Popular Stories